Watchlist
TWST · Twist Bioscience Corporation
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-06-11 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record. Research has since re-rated the name medium; the record keeps the graded tier.
Current thesis
Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and Evercore stepped aside on valuation. The 2026-08-03 Q3 print is the binary that decides whether AI orders show up in the total revenue line.
Kill line
A weekly close below $80 — the old all-time-high ceiling that became support on the late-June breakout — voids the AI-order re-rating leg. Secondary: the 2026-08-03 Q3 FY26 print showing total revenue growth still stuck near +19% with no inflection from AI accounts.
Pick status
Played out resolved published kill line did not fire graded at low · since re-rated medium How this is scored →Latest analysis and events for TWST —
As of 20 September 2026, the latest FrontierPicks analysis for Twist Bioscience Corporation (TWST): Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and Evercore stepped aside on valuation. The 2026-08-03 Q3 print is the binary that decides whether AI orders show up in the total revenue line.
Kill line: A weekly close below $80 — the old all-time-high ceiling that became support on the late-June breakout — voids the AI-order re-rating leg. Secondary: the 2026-08-03 Q3 FY26 print showing total revenue growth still stuck near +19% with no inflection from AI accounts.
Next dated event on file: — catalyst in 10d.
Current Thesis
Twist Bioscience’s artificial-intelligence laboratory-services story now has a TuneLab ordering channel; repeat orders, fiscal fourth-quarter revenue delivery and operating improvement must validate the re-rating. On 2026-09-16, Twist announced that participants in Eli Lilly’s TuneLab can order antibody-characterization services using preferred protocols and pricing. That establishes a route to commercial demand, although the announcement disclosed no contract value or minimum purchase commitment. Twist announcement
The inference is that the narrative is accelerating — the 2026-09-16 agreement adds a commercial channel to the earlier Anthropic evaluator story, and the supplied adjusted market series closed at its 52-week high of $166.99 on 2026-09-18. This supersedes the 2026-09-06 note’s description of an announcement rally that had unwound. Price recovery is measured; recurring revenue attributable to the new channel remains unquantified.
The case counts as demonstrated when reported fiscal Q4 revenue reaches at least the company’s $123 million guidance floor, adjusted operating earnings reach the promised breakeven milestone, and management documents repeat AI-customer orders. Those tests come from the 2026-08-03 guidance and the newly announced ordering channel. The market invalidation is a weekly close below $125.29, the pre-Anthropic announcement zone’s upper boundary identified in the 2026-09-06 research.
Bullish and bearish views on Twist Bioscience Corporation
The model's bull view on Twist Bioscience Corporation (TWST), in brief: An explicit customer ordering route. The 2026-09-16 TuneLab agreement lets participating companies commission Twist antibody services. This supports the commercial-channel thesis, without establishing its revenue contribution. Company release Growth already reaches reported… The bear view: Commercial scale remains undisclosed. Twist’s 2026-09-16 release gives no guaranteed order volume or revenue contribution. An ordering mechanism cannot establish customer adoption or repeat purchasing on its own. Company release The market exceeds updated expectations. The… Both cases follow in full.
Bull Case
- An explicit customer ordering route. The 2026-09-16 TuneLab agreement lets participating companies commission Twist antibody services. This supports the commercial-channel thesis, without establishing its revenue contribution. Company release
- Growth already reaches reported revenue. Fiscal Q3 revenue was $118.376 million, up 23% year over year, while DNA Synthesis and Protein Solutions generated $56.6 million, up 39%; gross margin was 52.8%, according to the 2026-08-03 results. These are consolidated and segment measurements, rather than a separately disclosed TuneLab revenue stream. Filed results
- Analyst expectations have moved higher. On 2026-09-17, Leerink’s Puneet Souda raised the firm’s target to $160 from $120 and retained Outperform after management meetings. The interpretation that AI drug discovery remains early in its development belongs to Leerink. The Fly report
Bear Case
- Commercial scale remains undisclosed. Twist’s 2026-09-16 release gives no guaranteed order volume or revenue contribution. An ordering mechanism cannot establish customer adoption or repeat purchasing on its own. Company release
- The market exceeds updated expectations. The 2026-09-18 adjusted close of $166.99 exceeds Leerink’s 2026-09-17 target of $160 and UBS’s $144 target reported on 2026-09-09. Those comparisons establish the distance between price and named forecasts; they do not establish overvaluation. Analyst actions
- Breakeven remains a delivery test. The 2026-08-03 results reaffirmed fiscal Q4 breakeven in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), following a fiscal Q3 adjusted EBITDA loss of $11.3 million. Failure to reach that milestone would contradict the operating-improvement component of the thesis. Filed results
Setup & Price Structure
The supplied adjusted daily series records a $166.99 close and 52-week high on 2026-09-18, a three-month advance of 96.1%, and a 14-day relative strength index (RSI) of 70.0. These measurements establish strong momentum. They do not measure ownership concentration, short positioning or the durability of demand.
Benzinga coverage clustered around the 2026-09-16 TuneLab announcement and stock-mover articles dated 2026-09-16 and 2026-09-17. That is observable attention; the sample is too small to support a retail-crowding claim. Trading volume, fund flows and moving-average values are unavailable in the supplied evidence, so neither expanding participation nor distance above a rising moving average is established.
The historical $118.57–$125.29 pre-announcement zone comes from the 2026-09-06 published research. A weekly close below $125.29 would return the stock into that earlier zone and invalidate this renewed re-rating thesis. The September 18 high alone does not establish a new support shelf.
Catalyst Calendar (next 30 days)
- 2026-09-30 — Fiscal fourth-quarter end. This closes the measurement period for the $123–124 million revenue guidance and adjusted EBITDA breakeven objective reaffirmed on 2026-08-03. It is an accounting deadline, not an earnings-release date. Filed results
As checked on 2026-09-20, the company’s event calendar lists the 2026-09-15 Baird conference as a past event and provides no confirmed reporting date within the next 30 days. Fiscal Q4 results are the next financial test, but an exact publication date is not established. Company event calendar
What Would Change Our Mind
A return into the pre-Anthropic announcement zone would break the renewed market re-rating: a weekly close below $125.29 is the observable condition. That boundary refers to the historical market structure documented on 2026-09-06, rather than an assumed moving average or a newly inferred support level.
Financial confirmation requires the fiscal Q4 report to meet the revenue floor and adjusted EBITDA milestone specified above, with disclosed repeat AI-customer orders. Revenue below $123 million or another adjusted EBITDA loss would contradict the 2026-08-03 delivery commitments. Results without repeat-order evidence would leave the commercial-adoption thesis unresolved, even if the financial guidance were met.
Correlation Notes
This remains a single-name setup: the 2026-09-16 TuneLab agreement supplies a company-specific demand channel, while the available evidence contains no peer-return series or measured correlation. The second-order AI classification describes the connection between model development and physical laboratory services; it does not establish that TWST tracks semiconductor or data-center equities. Agreement details
The 2026-08-03 results also reported $61.8 million of next-generation sequencing revenue, growing 12% year over year. That business line prevents the reported revenue base from being treated as a pure AI-demand measurement; any claim that an AI-sector rally alone explains TWST requires evidence beyond the available single-name observations. Filed results
Notes
- Adjusted EBITDA breakeven excludes specified expenses and does not establish profitability under generally accepted accounting principles.
Related · shared themes
HPE
Hewlett Packard Enterprise Company
Hewlett Packard Enterprise's AI and networking earnings transition supports a repricing thesis that requires intact growth guidance and the first weekly close above $54.44 after the 2026-09-30 Investor Day. A weekly close below $50 invalidates the price thesis.
NTAP
NetApp, Inc.
NetApp's AI storage recovery requires delivery of September guidance before a weekly close below $164 breaks the thesis. Fiscal-Q2 revenue of at least $2.025 billion and non-GAAP gross margin of at least 67.0%, with the annual revenue outlook issued on 2026-09-02 maintained, would confirm the case.
XMTR
Xometry, Inc.
Xometry's AI manufacturing thesis requires enterprise adoption to deliver its August 4 guidance before a weekly close below $85. Third-quarter revenue of at least $234 million and adjusted EBITDA of at least $16 million, with the 33–34% full-year revenue-growth outlook maintained, would confirm the case.
DELL
Dell Technologies Inc.
Dell Technologies’ AI-server thesis requires roughly $19 billion of next-quarter revenue and infrastructure operating margin of at least 15.0%. The next quarterly results settle that case; September 21, 2026 index inclusion does not resolve the delivery or margin test.